NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Fore Biotherapeutics

Fore Biotherapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://fore.bio/

Last Round

Series D-2

Extension

Jul 7, 2026

Est. Valuation

$75M

Total Funding Raised

$249.9M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Fore Biotherapeutics is a biotechnology company that develops precision oncology therapies for patients with rare, unaddressed tumor mutations.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Application

Keywords

precision oncologyBRAF inhibitortargeted therapysmall-molecule inhibitorBRAF mutationsfunctional genomicsdrug developmentAI drug discoverytarget identificationclinical-stage biotechcentral nervous system tumorsCNS tumorsdrug in-licensingPhase 2 clinical trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fore Biotherapeutics Comps

Public and private peers based on sector, stage, and business model.

Fore Biotherapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Fore Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series D-2 ExtensionJul 7, 2026
Series DMay 22, 2025
Series DAug 23, 2023
Series CSep 21, 2020
VC RoundApr 30, 2018
Series A
Jun 22, 2016

Key People

Founding team and executive leadership

Michael Byrnes

Chief Financial Officer

Executive Team

Fore Biotherapeutics Investors

Notable investors and investment history

Fore Biotherapeutics investors
InvestorRounds
SymBiosis Capital ManagementSeries D-2 Extension
Samsung Securities Co., Ltd.Series D, Series D-2 Extension
TaiAx CapitalSeries D-2 Extension
Bio Capital Impact FundVC Round
Cormorant Asset ManagementSeries D, Series C, Series D-2 Extension
3B FUTURE Health FundSeries D, Series D-2 Extension, VC Round
Pontifax Venture CapitalVC Round, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 7, 2026

    $67M round led by Medicxi, SR One, and SymBiosis Capital Management.

  • Jun 20, 2026

    Monthly visitors increased 71% MoM.

Fore Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Fore Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Fore Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range56
Year Founded2011
Last FundingJul 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.